Scholarlink

This was a case with anaplastic thyroid carcinoma being treated with dabrafenib, trametinib, and pembrolizumab leading to bilateral anterior uveitis, optic neuritis and central serous retinopathy after 2 months. Patient improved with intravenous steroid and withholding pembrolizumab, topical difluprednate, and topical atropine, with vision returned to baseline post treatment. The decision was made not to rechallenge with pembrolizumab. Patient is still undergoing cancer treatment with marked clinical and radiographic improvement showing resolution of metastatic pulmonary disease and near resolution of lower neck disease at 1 month follow up post uveitis.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Uveitis Post Immune Checkpoint Inhibitor Therapy

  • 章节

  • 发表日期：

    2025年

查看全文
  • Zachary DeZeeuw,
  • Azadeh Razmandi,
  • Nagham Al-Zubidi

摘要

This was a case with anaplastic thyroid carcinoma being treated with dabrafenib, trametinib, and pembrolizumab leading to bilateral anterior uveitis, optic neuritis and central serous retinopathy after 2 months. Patient improved with intravenous steroid and withholding pembrolizumab, topical difluprednate, and topical atropine, with vision returned to baseline post treatment. The decision was made not to rechallenge with pembrolizumab. Patient is still undergoing cancer treatment with marked clinical and radiographic improvement showing resolution of metastatic pulmonary disease and near resolution of lower neck disease at 1 month follow up post uveitis.